Controversies surrounding GRAS often center around the perceived lack of oversight and transparency. Critics argue that allowing companies to self-determine GRAS status without mandatory FDA review could lead to biased assessments. Additionally, there are concerns about the sufficiency of long-term safety data and the potential for cumulative exposure to multiple GRAS substances. These controversies highlight the need for a balanced approach that ensures both innovation and safety.
